| [1] |
Sung H, Ferlay J, Siegel RL, et al. Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries[J]. CA Cancer J Clin, 2021, 71(3): 209-249.
|
| [2] |
闫超, 陕飞, 李子禹. 2020年中国与全球结直肠癌流行概况分析[J]. 中华肿瘤杂志, 2023, 45(3): 221-229.
|
| [3] |
中国临床肿瘤学会(CSCO)结直肠癌专家委员会. 可切除的进展期结直肠癌围手术期治疗专家共识(2019)[J]. 中华胃肠外科杂志, 2019, 22(8): 701-710.
|
| [4] |
Bhojnagarwala PS, Perales-Puchalt A, Cooch N, et al. A synDNA vaccine delivering neoAg collections controls heterogenous, multifocal murine lung and ovarian tumors via robust T cell generation[J]. Mol Ther Oncolytics, 2021, 21: 278-287.
|
| [5] |
Kang HM, Kim GH, Jeon HK, et al. Circulating tumor cells detected by lab-on-a-disc: role in early diagnosis of gastric cancer[J]. PLoS One, 2017, 12(6): e0180251.
|
| [6] |
Liu MC, Oxnard GR, Klein EA, et al. Sensitive and specifc multi-cancer detection and localization using methylation signatures in cell-free DNA[J]. Ann Oncol, 2020, 31(6): 745-759.
|
| [7] |
Willis J, Lefterova MI, Artyomenko A, et al. Validation of microsatellite instability detection using a comprehensive plasma-based genotyping panel[J]. Clin Cancer Res, 2019, 25(23): 7035-7045.
|
| [8] |
Hu D, Lou X, Meng N, et al. Peripheral blood-based DNA methylation of long non-coding RNA H19 and metastasisassociated lung adenocarcinoma transcript 1 promoters are potential non-invasive biomarkers for gastric cancer detection[J]. Cancer Control, 2021, 28: 10732748211043667.
|
| [9] |
Zhang L, Li C, Su X. Emerging impact of the long noncoding RNA MIR22HG on proliferation and apoptosis in multiple human cancers[J]. J Exp Clin Cancer Res, 2020, 39(1): 271.
|
| [10] |
Loktionov A. Biomarkers for detecting colorectal cancer non-invasively: DNA, RNA or proteins?[J]. World J Gastrointest Oncol, 2020, 12(2): 124-148.
|
| [11] |
Bartak BK, Kalmar A, Peterfifia B, et al. Colorectal adenoma and cancer detection based on altered methylation pattern of SFRP1, SFRP2, SDC2, and PRIMA1 in plasma samples[J]. Epigenetics, 2017, 12(9): 751-763.
|
| [12] |
Zhao G, Li H, Yang Z, et al. Multiplex methylated DNA testing in plasma with high sensitivity and specifificity for colorectal cancer screening[J]. Cancer Med, 2019, 8(12): 5619-5628.
|
| [13] |
Xu LM, Li XB, Li XC, et al. RNA profling of blood platelets noninvasively diferentiates colorectal cancer from healthy donors and noncancerous intestinal diseases: a retrospective cohort study[J]. Genome Med, 2022, 14(1): 26.
|
| [14] |
Onidani K, Shoji H, Kakizaki T, et al. Monitoring of cancer patients via next‐generation sequencing of patient‐derived circulating tumor cells and tumor DNA[J]. Cancer Sci, 2019, 110(8): 2590-2599.
|
| [15] |
Benson AB, Venook AP, Al-Hawary MM, et al. rectal cancer, version 2.2022, NCCN clinical practice guidelines in oncology[J]. J Natl Compr Canc Netw, 2022, 20(10): 1139-1167.
|
| [16] |
Fu Y, Ye YD, Liu XR, et al. Analyzing microsatellite instability and gene mutation in circulating cell-free DNA to monitor colorectal cancer progression[J]. Transl Cancer Res, 2021, 10(6): 2812-2821.
|
| [17] |
Parikh AR, van Seventer EE, Boland GM, et al. Minimal residual disease detection using a plasma-only circulating tumor DNA assay in colorectal cancer patients[J].Clin Cancer Res, 2021, 27(20): 5586-5594.
|
| [18] |
Tie J, Wang Y, Tomasetti C, et al. Circulating tumor DNA analysis detects minimal residual disease and predicts recurrence in patients with stage Ⅱ colon cancer[J]. Sci Transl Med, 2016, 8(346): 346ra92.
|
| [19] |
Chen G, Peng JJ, Xiao Q, et al. Postoperative circulating tumor DNA as markers of recurrence risk in stages Ⅱ to Ⅲ colorectal cancer[J]. J Hematol Oncol, 2021, 14(1): 80.
|
| [20] |
Sun L, Fang Y, Wang X, et al. miR-302a inhibits metastasis and cetuximab resistance in colorectal cancer by targeting NFIB and CD44[J]. Theranostics, 2019, 9(26): 8409-8425.
|
| [21] |
Wang XY, Zhang HY, Yang HO, et al. Exosome-delivered circRNA promotes glycolysis to induce chemoresistance through the miR-122-PKM2 axis in colorectal cancer[J]. Mol Onco, 2020, 14(3): 539-555.
|
| [22] |
Xian ZY, Hu B, Wang T, et al. lncRNA UCA1 contributes to 5-fluorouracil resistance of colorectal cancer cells through miR-23b-3p/ZNF281 Axis[J]. OncoTargets and Therapy, 2020, 13: 7571-7583.
|
| [23] |
Jiang ZP, Li L, Hou ZH, et al. LncRNA HAND2-AS1 inhibits 5-fluorouracil resistance by modulating miR-20a/PDCD4 axis in colorectal cancer[J]. Cell Signal, 2020, 66: 109483.
|
| [24] |
Deng X, Kong FY, Li S, et al. A KLF4/PiHL/EZH2/HMGA2 regulatory axis and its function in promoting oxaliplatin-resistance of colorectal cancer[J]. Cell Death Dis, 2021, 12(5): 485.
|
| [25] |
Cai M, Hu WL, Huang CJ, et al. NcRNA MCF2L-AS1/miR-105/ IL-1β axis regulates colorectal cancer cell oxaliplatin resistance[J]. Cancer Manag Res, 2021, 13: 8685-8694.
|
| [26] |
Camera S, Akin Telli T, Wof E, et al. Prognostic value of the pace of tumor progression as assessed by serial (18)F-FDG PET/CT scan and liquid biopsy in refractory colorectal cancer: the CORIOLAN trial[J]. Cancers (Basel), 2020, 12(10): 2752.
|
| [27] |
Yu JZ, Zhang J, Peng T, et al. Predictive value of circulating tumor cells in prognosis of stage Ⅲ/Ⅳ colorectal cancer after oxaliplatin-based first-line chemotherapy[J]. In Vivo, 2022, 36(2): 806-813.
|
| [28] |
Spindler KLG, Pallisgaard N, Appelt AL, et al. Clinical utility of KRAS status in circulating plasma DNA compared to archival tumour tissue from patients with metastatic colorectal cancer treated with anti-epidermal growth factor receptor therapy[J]. Eur J Cancer, 2015, 51(17): 2678-2685.
|
| [29] |
Petit J, Carroll G, Gould T, et al. Cell-free DNA as a diagnostic blood-based biomarker for colorectal cancer: a systematic review[J]. J Surg Res, 2019, 236: 184-197.
|
| [30] |
Xu F, Yu SS, Han JY, et al. Detection of circulating tumor DNA methylation in diagnosis of colorectal cancer[J]. Clin Transl Gastroenterol, 2021, 12(8): e00386.
|
| [31] |
Jin SN, Zhu DW, Shao FG, et al. Efficient detection and post-surgical monitoring of colon cancer with a multi-marker DNA methylation liquid biopsy[J]. Proc Natl Acad Sci USA, 2021, 118(5): e2017421118.
|
| [32] |
Wang LY, Cho KB, Li Y, et al. Long noncoding RNA (lncRNA)-mediated competing endogenous RNA networks provide novel potential biomarkers and therapeutic targets for colorectal cancer[J]. Int J Mol Sci, 2019, 20(22): 5758.
|
| [33] |
Bardelli A, Pantel K. Liquid biopsies, what we do not know (yet)[J]. Cancer Cell, 2017, 31(2): 172-179.
|
| [34] |
Dang DK, Park DH. Circulating tumor DNA: current challenges for clinical utility[J]. J Clin Invest, 2022, 132(12): e154941.
|
| [35] |
Nikanjam M, Kato S, Kurzrock R. Liquid biopsy: current technology and clinical applications[J]. J Hematol Oncol, 2022, 15(1): 131.
|
| [36] |
Perry JP. Emerging stool-based and blood-based non-invasive DNA tests for colorectal cancer screening: the importance of cancer prevention in addition to cancer detection[J]. Abdom Radiol (NY), 2016, 41(8): 1441-1444.
|
| [37] |
Bahnassy AA, Salem SE, Mohanad M, et al. Prognostic signifcance of circulating tumor cells (CTCs) in Egyptian non-metastatic colorectal cancer patients: a comparative study for four diferent techniques of detection (Flowcytometry, Cell Search, Quantitative Real-time PCR and Cytomorphology)[J]. Exp Mol Pathol, 2019, 106: 90-101.
|
| [38] |
Yao YM, Zhu X, Liu WX, et al. Meta-analysis of the prognostic value of circulating tumor cells in gastrointestinal cancer[J]. Medicine(Baltimore), 2022, 101(42): e31099.
|
| [39] |
Adashek JJ, Janku F, Kurzrock R. Signed in blood: circulating tumor DNA in cancer diagnosis, treatment and screening[J]. Cancers, 2021, 13(14): 3600.
|
| [40] |
IJzerman MJ, de Boer J, Azad A, et al. Towards routine implementation of liquid biopsies in cancer management: it is always too early, until suddenly it is too late[J]. Diagnostics, 2021, 11(1): 103.
|
| [41] |
Falkener LG, Howells LM, Pepper C, et al. The utility of ctDNA in detecting minimal residual disease following curative surgery in colorectal cancer: a systematic review and meta-analysis[J]. Br J Cancer, 2023, 128(2): 297-309.
|
| [42] |
Schraa SJ, van Rooijen KL, Koopman M, et al. Cell-free circulating (Tumor) DNA before surgery as a prognostic factor in non-metastatic colorectal cancer: a systematic review[J]. Cancers(Basel), 2022, 14(9): 2218.
|
| [43] |
Van der Pol Y, Moldovan N, Ramaker J, et al. The landscape of cellfree mitochondrial DNA in liquid biopsy for cancer detection[J]. Genome Biol, 2023, 24(1): 229.
|
| [44] |
Erve IV, Medina JE, Leal A, et al. Metastatic colorectal cancer treatment response evaluation by ultra-deep sequencing of cell-free DNA and matched white blood cells[J]. Clin Cancer Res, 2023, 29(5): 899-909.
|
| [45] |
Manca P, Corallo S, Lonardi S, et al. Variant allele frequency in baseline circulating tumour DNA to measure tumour burden and to stratify outcomes in patients with RAS wild-type metastatic colorectal cancer: a translational objective of the Valentino study[J]. Br J Cancer, 2022, 126(3): 449-455.
|
| [46] |
Aziz Z, Wagner S, Agyekum A, et al. Cost-effectiveness of liquid biopsy for colorectal cancer screening in patients who are unscreened[J]. 2023, JAMA Netw Open, 2023, 6(11): e2343392.
|
| [47] |
Fagery M, Khorshidi HA, Wong SQ, et al. Health economic evidence and modeling challenges for liquid biopsy assays in cancer management: a systematic literature review[J]. Pharmacoeconomics, 2023, 41(10): 1229-1248.
|